Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2022-08-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
未来三年（2022年-2024年）股东回报规划
Governance Information Classification · 95% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2022-2024). It discusses profit distribution principles, decision-making and supervision mechanisms, dividend policies, and conditions for cash and stock dividends. It references relevant laws and regulations and includes governance aspects such as board and shareholder approvals, independent director opinions, and disclosure requirements. The document is not a financial report with actual financial statements or results, nor is it an announcement of a report publication. It is a formal policy document related to governance and shareholder returns. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including dividend and shareholder return policies.
2022-08-12 Chinese
关于最近五年证券监管部门和证券交易所采取监管措施或处罚情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 盈康生命科技股份有限公司 regarding regulatory measures and penalties taken against the company by securities regulatory authorities and stock exchanges over the past five years. It details specific regulatory letters, disciplinary actions, and corrective measures but does not contain financial statements or detailed financial performance data. The document is relatively short (3175 characters) and serves as a disclosure of regulatory history rather than a full financial report or audit. It does not fit categories like Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is also not a report publication announcement since it contains substantive content about regulatory actions. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure that does not fit other specific categories.
2022-08-12 Chinese
关于择期召开股东大会的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (532 characters) regarding the scheduling of a shareholders' meeting to discuss a specific agenda item related to a private placement of shares. It states that a formal notice of the shareholders' meeting will be issued later. There is no detailed financial data, no full report, and it is not a voting result announcement. The document is an announcement about convening a shareholders' meeting, specifically related to capital raising via private placement. This fits best under Capital/Financing Update (CAP) as it concerns financing activities and the scheduling of a meeting to approve such activities.
2022-08-12 Chinese
关于向特定对象发行股票摊薄即期回报的风险提示及采取填补措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 盈康生命科技股份有限公司 regarding a planned issuance of shares to specific investors. It discusses the risk of dilution of immediate returns due to this issuance, the assumptions and financial impact analysis, risk warnings, necessity and feasibility of the issuance, use of raised funds, measures to mitigate dilution risk, and commitments by controlling shareholders and management. The document references regulatory guidelines and includes detailed financial metrics projections related to the issuance. It is not a full financial report like an Annual or Interim Report, nor is it a simple announcement of a report publication. It is a detailed disclosure about a capital raising event and its impact, which fits the category of Capital/Financing Update (CAP). The document length (6785 characters) and content depth support this classification with high confidence.
2022-08-12 Chinese
截至2022年6月30日止前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Usage Verification Report". It includes a verification opinion from an accounting firm (和信会计师事务所) regarding the use of funds raised in a previous financing round, specifically up to June 30, 2022. The report references compliance with regulations issued by the China Securities Regulatory Commission (CSRC) about fundraising usage reports. The content includes detailed financial data on the amount raised, usage, remaining funds, and investment projects, along with auditor's verification and conclusions. This type of document is a standalone audit or verification report on the use of previously raised capital, not a full annual or interim financial report, nor a simple announcement. It fits the category of an Audit Report / Information (AR) as it is a verification report by auditors on a specific financial aspect (fundraising usage). The document length (5714 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence. H1 2022
2022-08-12 Chinese
2022年向特定对象发行股票募集资金使用可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 年向特定对象发行股票募集资金使用可行性分析报告" which translates to "2022 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of Shares." It discusses the company's plan to raise funds through a private placement (specific object issuance of shares), the necessity and feasibility of the fundraising, the impact on the company's financial and operational status, and compliance with relevant laws and regulations. The document is focused on the capital raising activity and the use of proceeds from the issuance of shares. It is not an earnings release, annual report, or management discussion, nor is it a regulatory filing or announcement of a report publication. It is a detailed report analyzing the feasibility and use of funds from a capital raising event. Therefore, the document fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising and capital structure changes. The document length is 3307 characters, which is sufficient for a detailed report rather than a brief announcement. Hence, the classification is CAP with high confidence.
2022-08-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.